MedPath

BIOMAY AG

BIOMAY AG logo
🇦🇹Austria
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.biomay.com

Clinical Trials

13

Active:8
Completed:5

Trial Phases

2 Phases

Phase 1:4
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (50.0%)
Phase 2
4 (50.0%)

Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response

Phase 2
Completed
Conditions
Hypersensitivity
First Posted Date
2015-12-31
Last Posted Date
2017-01-19
Lead Sponsor
Biomay AG
Target Recruit Count
130
Registration Number
NCT02643641
Locations
🇦🇹

Vienna Challenge Chamber, Vienna, Austria

Phase II Study of Grass Pollen Allergy Vaccine BM32

Phase 2
Completed
Conditions
Grass Pollen Allergy
First Posted Date
2012-02-27
Last Posted Date
2015-12-18
Lead Sponsor
Biomay AG
Target Recruit Count
181
Registration Number
NCT01538979
Locations
🇦🇹

Universitätsklinik für Dermatologie und Allergologie, Graz, Austria

🇦🇹

Medical University, Vienna, Austria

🇧🇪

Allergy Network Ghent University Hospital Ghent, Dept. Otorhiolaryngologie, Ghent, Belgium

and more 8 locations

Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy

Phase 2
Completed
Conditions
Grass Pollen Allergy
First Posted Date
2011-10-03
Last Posted Date
2013-01-14
Lead Sponsor
Biomay AG
Target Recruit Count
79
Registration Number
NCT01445002
Locations
🇦🇹

Allergy Center Vienna West, Vienna, Austria

Skin Test Study of BM32

Phase 1
Completed
Conditions
Hypersensitivity
First Posted Date
2011-05-10
Last Posted Date
2015-12-18
Lead Sponsor
Biomay AG
Target Recruit Count
60
Registration Number
NCT01350635
Locations
🇦🇹

Medical University, Vienna, Austria

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.